JP2024519140A5 - - Google Patents
Info
- Publication number
- JP2024519140A5 JP2024519140A5 JP2023572596A JP2023572596A JP2024519140A5 JP 2024519140 A5 JP2024519140 A5 JP 2024519140A5 JP 2023572596 A JP2023572596 A JP 2023572596A JP 2023572596 A JP2023572596 A JP 2023572596A JP 2024519140 A5 JP2024519140 A5 JP 2024519140A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- cycloalkyl
- heteroaryl
- heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163194138P | 2021-05-27 | 2021-05-27 | |
| US63/194,138 | 2021-05-27 | ||
| US202163203667P | 2021-07-27 | 2021-07-27 | |
| US63/203,667 | 2021-07-27 | ||
| US202163290587P | 2021-12-16 | 2021-12-16 | |
| US63/290,587 | 2021-12-16 | ||
| PCT/CA2022/050864 WO2022246576A1 (en) | 2021-05-27 | 2022-05-27 | Camptothecin analogues, conjugates and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024519140A JP2024519140A (ja) | 2024-05-08 |
| JP2024519140A5 true JP2024519140A5 (enExample) | 2025-08-01 |
Family
ID=84229147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023572596A Pending JP2024519140A (ja) | 2021-05-27 | 2022-05-27 | カンプトテシン類似体、複合体及び使用の方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240269309A1 (enExample) |
| EP (1) | EP4347601A4 (enExample) |
| JP (1) | JP2024519140A (enExample) |
| KR (1) | KR20240031235A (enExample) |
| AU (1) | AU2022282813A1 (enExample) |
| BR (1) | BR112023024433A2 (enExample) |
| CA (1) | CA3177067A1 (enExample) |
| IL (1) | IL308734A (enExample) |
| MX (1) | MX2023013738A (enExample) |
| WO (1) | WO2022246576A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023018676A2 (pt) | 2021-03-18 | 2023-10-10 | Seagen Inc | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco |
| JP2024532768A (ja) * | 2021-08-19 | 2024-09-10 | ハイナン シムセレ ザイミン ファーマシューティカル カンパニー リミテッド | カンプトテシン誘導体、その薬物組成物およびその応用 |
| CA3241157A1 (en) * | 2021-12-16 | 2023-06-22 | Wei Zhou | Camptothecin compound and conjugate thereof |
| WO2023178289A2 (en) * | 2022-03-17 | 2023-09-21 | Seagen Inc. | Camptothecin conjugates |
| AU2023239448A1 (en) | 2022-03-25 | 2024-11-07 | Zymeworks Bc Inc. | Antibody-drug conjugates targeting folate receptor alpha and methods of use |
| JP2025515988A (ja) * | 2022-05-13 | 2025-05-23 | シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド | カンプトテシン化合物、その調製方法及びその使用 |
| CN116675727A (zh) * | 2022-12-28 | 2023-09-01 | 广州医科大学 | 一种以不保护氨基酸为氨组分合成酰胺和/或多肽的方法 |
| CN117599058A (zh) * | 2023-03-09 | 2024-02-27 | 兰州大学 | 喜树碱类衍生物在制备治疗膀胱癌药物中的应用 |
| EP4720075A1 (en) * | 2023-05-26 | 2026-04-08 | NJ Bio, Inc. | Topoisomerase inhibitors, methods of making, and methods of use thereof |
| EP4729521A1 (en) * | 2023-06-13 | 2026-04-22 | Chengdu Brilliant Pharmaceutical Co., Ltd. | Camptothecin derivative for treating or preventing cancer, and antibody-drug conjugate thereof |
| WO2025078841A2 (en) | 2023-10-11 | 2025-04-17 | Antikor Biopharma Limited | Antibodies, conjugates, and uses thereof |
| US20250121088A1 (en) * | 2023-10-11 | 2025-04-17 | Minerva Biotechnologies Corporation | Anti-muc1* antibody drug complexes and uses thereof |
| WO2025081282A1 (en) * | 2023-10-19 | 2025-04-24 | Zymeworks Bc Inc. | Anti-napi2b antibody-drug conjugates and methods of use |
| WO2025235686A1 (en) * | 2024-05-07 | 2025-11-13 | Aarvik Therapeutics, Inc. | Fluorocamptothecin compounds, conjugates, and methods thereof |
| KR20250170534A (ko) * | 2024-05-28 | 2025-12-05 | 한미약품 주식회사 | 항종양 활성을 지니는 신규한 설파마이드 캄토테신 유도체 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136978A (en) * | 1993-06-30 | 2000-10-24 | University Of Pittsburgh | Camptothecin analogs and methods of preparation thereof |
| GB9402934D0 (en) * | 1994-02-16 | 1994-04-06 | Erba Carlo Spa | Camptothecin derivatives and process for their preparation |
| JP2002255821A (ja) * | 2001-03-06 | 2002-09-11 | Yakult Honsha Co Ltd | 抗癌剤耐性癌に対する治療剤 |
| KR102648564B1 (ko) * | 2017-03-24 | 2024-03-19 | 씨젠 인크. | 글루쿠로니드 약물-링커의 제조 공정 및 그 중간물 |
| SG11202110922QA (en) * | 2019-04-26 | 2021-10-28 | Immunogen Inc | Camptothecin derivatives |
| CN110128501A (zh) * | 2019-05-21 | 2019-08-16 | 北京海美源医药科技有限公司 | 一种靶向fap酶的喜树碱类化合物及其制备方法和应用 |
| BR112022025583A2 (pt) * | 2020-06-19 | 2023-01-03 | Hangzhou Dac Biotech Co Ltd | Conjugado de molécula de ligação à superfície celular e análogo de camptotecina, composto conjugável, célula de tumor, composição farmacêutica, agente quimioterapêutico, e, agentes sinergísticos |
| EP4257154A4 (en) * | 2021-02-09 | 2026-04-22 | Medilink Therapeutics Suzhou Co Ltd | CONJUGATED WITH A BIOACTIVE SUBSTANCE, ITS PREPARATION PROCESS AND ITS USE |
| CA3213625A1 (en) * | 2021-03-18 | 2022-09-22 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| EP4426727A2 (en) * | 2021-11-03 | 2024-09-11 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
-
2022
- 2022-05-27 IL IL308734A patent/IL308734A/en unknown
- 2022-05-27 BR BR112023024433A patent/BR112023024433A2/pt unknown
- 2022-05-27 EP EP22810026.9A patent/EP4347601A4/en active Pending
- 2022-05-27 AU AU2022282813A patent/AU2022282813A1/en active Pending
- 2022-05-27 KR KR1020237044336A patent/KR20240031235A/ko active Pending
- 2022-05-27 CA CA3177067A patent/CA3177067A1/en active Pending
- 2022-05-27 JP JP2023572596A patent/JP2024519140A/ja active Pending
- 2022-05-27 MX MX2023013738A patent/MX2023013738A/es unknown
- 2022-05-27 US US18/562,049 patent/US20240269309A1/en active Pending
- 2022-05-27 WO PCT/CA2022/050864 patent/WO2022246576A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024519140A5 (enExample) | ||
| JP2025525406A5 (enExample) | ||
| JP2024520481A5 (enExample) | ||
| JP2024052757A5 (enExample) | ||
| JP2021534124A5 (enExample) | ||
| CA2496676A1 (en) | 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands | |
| CN102574837B (zh) | 新的5-氟尿嘧啶衍生物 | |
| JP2007505138A5 (enExample) | ||
| CA2343414A1 (en) | Fc receptor modulators and uses thereof | |
| ZA200108774B (en) | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors. | |
| CA2568832A1 (en) | Indole derivatives as antiviral agents | |
| JP2020500869A5 (enExample) | ||
| JP2024521895A5 (enExample) | ||
| JP2005511545A5 (enExample) | ||
| RU2323211C2 (ru) | Новые производные бензимидазола, способы их получения, их применение и содержащая их фармацевтическая композиция | |
| DD220308A5 (de) | Verfahren zur herstellung von n(piperidinylalkyl)-carboxamiden | |
| CN106456613B (zh) | 制备环缩肽的方法 | |
| JP2000510129A (ja) | ジスタマイシン誘導体、その調製方法並びに抗腫瘍薬及び抗ウイルス薬としてのその使用 | |
| JPWO2019189867A1 (ja) | ビスイミノビオチン化合物の薬物送達用の用途 | |
| CA2191454C (en) | Phosphinic acid derivatives and their use as endothelin converting enzyme inhibitors | |
| JP2002521470A (ja) | 硫化ジスタマイシン誘導体、それの製造方法、ならびにそれの抗腫瘍薬としての使用 | |
| JP2022521474A5 (enExample) | ||
| JP7815213B2 (ja) | ベンジルアミン誘導体、その調製方法およびその用途 | |
| JP2024540402A5 (enExample) | ||
| JP2004504298A5 (enExample) |